Welcome to our dedicated page for Citius Pharmaceuticals news (Ticker: CTXR), a resource for investors and traders seeking the latest updates and insights on Citius Pharmaceuticals stock.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company focused on first-in-class critical care products and holds a majority interest in Citius Oncology, Inc. News about CTXR often centers on regulatory milestones, clinical progress, and financing activities that support the development and commercialization of its therapies.
Recent company communications emphasize the FDA approval of LYMPHIR (denileukin diftitox-cxdl) for adult patients with relapsed or refractory Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy, and the subsequent U.S. commercial launch executed by Citius Oncology. CTXR news also highlights the late-stage status of Mino-Lok, a catheter lock solution for catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for hemorrhoid relief, along with completed pivotal and Phase 2b trials.
Investors following CTXR can expect updates on capital raises such as registered direct offerings and warrant issuances, which the company states are intended to fund the commercial launch of LYMPHIR, regulatory and milestone payments, and broader development initiatives. Filings and press releases also describe ongoing engagement with the FDA regarding next steps for Mino-Lok and Halo-Lido.
This news feed aggregates press releases, regulatory disclosures, and other public announcements related to Citius Pharmaceuticals and its majority-owned oncology subsidiary. For those tracking CTXR, it provides a centralized view of developments across oncology, critical care, clinical trials, and corporate finance. Regular review of this page can help readers monitor how Citius Pharmaceuticals advances its portfolio and supports the commercialization of LYMPHIR through Citius Oncology.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced its inclusion in the Russell 2000 Index effective June 28, 2021. This milestone is expected to enhance the company's visibility and attract a broader investment community. The Russell indexes are utilized by institutional investors for asset management and benchmark strategies. Citius focuses on developing first-in-class critical care products, including Mino-Lok®, currently in a Phase 3 trial for treating catheter-related infections. The company also aims to advance stem cell therapy for respiratory conditions.
Citius Pharmaceuticals (Nasdaq: CTXR) announced receiving the Best Poster Award at the ISCT 2021 Annual Meeting for their poster titled "Novel Induced-Mesenchymal Stem Cells (i-MSCs) Attenuate Severity of ARDS in Septic Sheep". Dr. Perenlei Enkhbaatar presented the findings, which highlighted significant improvements in clinical parameters for i-MSC treated animals. Citius is progressing its stem cell therapy for ARDS and has developed a cell bank to support future trials. The recognition underscores the company’s advancements and engagement in cell and gene therapy.
Citius Pharmaceuticals, Inc. (CTXR) announced its participation at the ISCT Annual Meeting on May 26-28, 2021, with a poster presentation on a study evaluating induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute lung injury. Interim results indicate promising safety and efficacy signals for i-MSCs in treating Acute Respiratory Distress Syndrome (ARDS), a serious condition with no FDA-approved therapies. The findings could pave the way for future clinical trials in ARDS patients.
Citius Pharmaceuticals (Nasdaq: CTXR) has appointed Ilanit Allen as Vice President of Corporate Communications and Investor Relations, effective immediately. Allen brings over 20 years of experience, having previously advised numerous life science companies. Under her leadership, the company aims to enhance financial communication and investor engagement, paving the way for potential growth with multiple milestones on the horizon. Andrew Scott will take on expanded responsibilities in business development while maintaining his role in investor relations.
Citius Pharmaceuticals, Inc. (CTXR) reported its fiscal Q2 2021 results, highlighting a strong balance sheet with $103.7 million in cash. The company raised approximately $96.5 million, extending its funding runway into 2023. Despite enrollment challenges in the Mino-Lok® Phase 3 trial due to COVID-19, they are on track for a Drug Monitoring Committee meeting and plan to file a New Drug Application in 2022. Citius is advancing several product candidates, including Halo-Lido and a novel stem cell therapy for ARDS, aiming to address significant medical needs.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) will participate in a fireside chat at the Gabelli Funds Virtual Microcap Symposium on May 18, 2021, at 10:30 am ET. CEO Myron Holubiak will discuss corporate strategy and key pipeline assets, including Mino-Lok®, an advanced treatment for catheter-related bloodstream infections, and NC i-MSC, a novel stem cell therapy for Acute Respiratory Distress Syndrome (ARDS), worsening due to COVID-19. Mino-Lok® is in a Phase 3 trial and has received Fast Track designation from the FDA. For registration, visit the event website.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced participation in the Benzinga Global Small Cap Conference on May 13-14, 2021. CEO Myron Holubiak will present on May 13 at 1:50 p.m. ET, focusing on the company's pipeline strategy, particularly a novel stem-cell program for treating Acute Respiratory Distress Syndrome (ARDS) associated with COVID-19. This condition currently lacks FDA-approved therapeutic options. Additionally, Citius's Mino-Lok® is undergoing a Phase 3 trial for catheter-related bloodstream infections.
Citius Pharmaceuticals (Nasdaq: CTXR) provided updates on its Mino-Lok® Phase 3 trial during a recent webinar, highlighting the growing interest from the clinical community. Mino-Lok is an antibiotic lock therapy aimed at salvaging central venous catheters (CVCs) in patients with catheter-related bloodstream infections (CRBSIs). Currently, no FDA-approved therapies exist for this purpose. The company believes that Mino-Lok could set a new standard in treating CRBSIs, emphasizing its potential to penetrate biofilms and maintain CVC access. The FDA has granted Mino-Lok Fast Track designation.
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced that its President and CEO, Myron Holubiak, participated in a Benzinga interview discussing the company's product pipeline, Covid-19 impact, and future milestones. The company focuses on critical care products, particularly in anti-infective treatments and stem cell therapy. Notably, its lead product, Mino-Lok®, is in a Phase III trial and has received Fast Track designation by the FDA. The interview is available on the Citius corporate website.
Citius Pharmaceuticals will participate in the Benzinga Biotech Small Cap Conference on March 24-25, 2021, where Executive Chairman Leonard Mazur will discuss the Phase 3 trial of Mino-Lok®, an antibiotic solution for catheter-related bloodstream infections. The trial is progressing as planned, with full enrollment expected this year. The U.S. market opportunity for Mino-Lok® is projected at $750 million, with a worldwide potential of $1.5 billion. Investors can register for the conference via the provided event website.